Risk factor
Very high price volatility
Profitability factor
Greatly overvalued vs peers
About
Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment engages in the provision...
Company Valuation
Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers.
Target Price
The average target price of ACRS is 7.2 and suggests 89% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increas
Buy
Sell